Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ECOZA vs CANDEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Imidazole antifungal inhibiting ergosterol synthesis via CYP51, disrupting fungal cell membrane permeability.
Candesartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to vasodilation and reduced blood pressure.
Topical treatment of tinea pedis, tinea cruris, tinea corporis, tinea versicolor, and cutaneous candidiasis
Hypertension,Heart failure (NYHA class II-IV and left ventricular systolic dysfunction, to reduce cardiovascular mortality)
For vulvovaginal candidiasis: One vaginal suppository (150 mg) inserted intravaginally at bedtime for 3 consecutive days. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily for 2-4 weeks.
Adults: 150 mg orally once daily
Terminal elimination half-life is approximately 24–30 hours, allowing for once-daily dosing.
Terminal elimination half-life is 20-30 hours (mean 24 hours) in adults; prolonged in hepatic impairment (up to 50 hours) and requires dose adjustment.
Not extensively metabolized; minimal systemic absorption after topical application.
Primarily metabolized by CYP2C9 to an inactive metabolite; also undergoes O-deethylation. Minimal hepatic metabolism, primarily excreted unchanged in bile and urine.
Primarily hepatic metabolism; <1% excreted renally as unchanged drug. Fecal excretion accounts for ~57% of metabolites.
Primarily hepatic metabolism via CYP2C9, with <1% excreted unchanged in urine. Approximately 70-80% eliminated in feces as metabolites, 20-30% in urine as metabolites.
Approximately 89–93% bound to plasma proteins, primarily albumin.
99% bound to albumin (primarily), also to alpha-1-acid glycoprotein.
Apparent volume of distribution is approximately 2–3 L/kg, indicating extensive tissue penetration.
Extensive: 1.5-2 L/kg, indicating wide distribution into tissues including skin, nails, and adipose tissue. Accumulates in stratum corneum and nails.
Oral bioavailability is approximately 37% (range 20–70%) due to first-pass metabolism; topical bioavailability is negligible systemically.
Oral: 99% (well absorbed); food does not affect absorption. No IV formulation due to poor water solubility; not administered topically for systemic effects.
No dosage adjustment required for renal impairment. Systemic absorption is minimal after topical or intravaginal use.
Cr Cl 30-60 m L/min: 100 mg once daily; Cr Cl 15-29 m L/min: 50 mg once daily; Cr Cl <15 m L/min: 50 mg every 48 hours
No dosage adjustment required for hepatic impairment due to minimal systemic absorption.
Child-Pugh A: no adjustment; Child-Pugh B: 100 mg once daily; Child-Pugh C: not recommended
Safety and efficacy in pediatric patients have not been established for vaginal use. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily; duration based on clinical response. Weight-based dosing not applicable.
Not established for children <18 years of age
No specific dose adjustment required; use same dosing as for younger adults. Monitor for local irritation or adverse effects.
No specific adjustment required; consider renal function and potential for increased sensitivity
None
Fetal toxicity: Drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.
For external use only; avoid contact with eyes; discontinue if hypersensitivity occurs.
Fetal toxicity,Hypotension in volume-depleted patients,Renal function impairment,Hyperkalemia,Avoid concomitant use with aliskiren in patients with diabetes
Known hypersensitivity to imidazole antifungals or any component of the formulation
Hypersensitivity to candesartan or any component,Concomitant use with aliskiren in patients with diabetes,Pregnancy
No clinically significant food interactions for topical econazole nitrate. Avoid alcohol if using oral antifungal concurrently (not applicable here).
No significant food interactions. Grapefruit juice does not interact. Avoid salt substitutes with potassium.
ECOZA (econazole nitrate) is pregnancy category C. First trimester: no adequate studies; avoid unless benefit outweighs risk. Second/third trimester: minimal absorption after topical application, unlikely to cause fetal harm; however, prolonged use near term is not recommended due to theoretical risk of premature ductus arteriosus closure if systemic absorption occurs.
Teratogenic risk profile for Candesartan (CANDEX) is based on its mechanism as an angiotensin II receptor blocker (ARB). First trimester: No increased risk of major congenital malformations from first-trimester exposure based on human data, but animal studies show fetal toxicity at high doses. Second and third trimesters: Known to cause fetal renal dysfunction, oligohydramnios, skull ossification defects, and neonatal renal failure. Use is contraindicated in pregnancy, especially after 20 weeks gestation.
Not known if econazole is excreted in human milk. M/P ratio not available. Due to low systemic absorption after topical use, risk to nursing infant is considered low. Caution if applied to breast area; avoid infant ingestion.
Excretion into breast milk is unknown; limited data may be available for similar ARBs but M/P ratio is not established. Due to risk of neonatal renal effects, use during breastfeeding is not recommended, especially in preterm infants or those with renal impairment. Alternative agents preferred.
No dose adjustment needed. Pharmacokinetic changes in pregnancy (e.g., increased skin blood flow, hydration) may slightly alter absorption but clinical significance is minimal. Use standard topical dosing as prescribed.
Pharmacokinetic changes in pregnancy (increased volume of distribution, renal blood flow) may require dose adjustments. However, due to fetotoxicity, candesartan is contraindicated in pregnancy, and no dose recommendation is provided. Alternative antihypertensives such as labetalol or nifedipine are preferred.
Ecoza (econazole nitrate) is a topical azole antifungal. Avoid use on open wounds or broken skin. Apply once daily for 4 weeks for tinea pedis; 2 weeks for tinea cruris/corporis. Do not use occlusive dressings. Monitor for local irritation, burning, or allergic contact dermatitis.
Candesartan is contraindicated in pregnancy (category D). Monitor renal function and electrolytes, especially in renal artery stenosis, heart failure, or volume depletion. May cause hypotension, especially in CHF patients. Dual blockade with ACEi increases risk of hyperkalemia and renal impairment.
Apply a thin layer to cleaned, dry affected area and surrounding skin once daily or as directed.,Wash hands before and after application unless treating hands.,Use for the full prescribed duration even if symptoms improve to prevent recurrence.,Avoid contact with eyes, mouth, or mucous membranes. If contact occurs, rinse with water.,Do not cover the treated area with bandages or wrappings unless instructed by your doctor.,Inform your doctor if symptoms persist after 2 weeks or worsen, or if severe irritation occurs.,Store at room temperature away from moisture and heat.
Take exactly as prescribed, usually once daily.,Avoid potassium supplements or salt substitutes containing potassium without medical advice.,If you become pregnant, stop taking and contact your doctor immediately.,May cause dizziness or lightheadedness; avoid driving until you know how you react.,Report any signs of angioedema (swelling of face, lips, throat) or fainting.,Stay hydrated, especially if experiencing diarrhea or vomiting.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ECOZA vs CANDEX, answered by our medical review team.
ECOZA is a Topical Antifungal that works by Imidazole antifungal inhibiting ergosterol synthesis via CYP51, disrupting fungal cell membrane permeability.. CANDEX is a Topical Antifungal and Corticosteroid that works by Candesartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to vasodilation and reduced blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ECOZA and CANDEX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ECOZA is: For vulvovaginal candidiasis: One vaginal suppository (150 mg) inserted intravaginally at bedtime for 3 consecutive days. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily for 2-4 weeks.. The standard adult dose of CANDEX is: Adults: 150 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ECOZA and CANDEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ECOZA is classified as Category C. ECOZA (econazole nitrate) is pregnancy category C. First trimester: no adequate studies; avoid unless benefit outweighs risk. Second/third trimester: minimal absorption after topic. CANDEX is classified as Category C. Teratogenic risk profile for Candesartan (CANDEX) is based on its mechanism as an angiotensin II receptor blocker (ARB). First trimester: No increased risk of major congenital malf. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.